55 results
Keyword Mavenclad Remove keyword
-
List item
Direct healthcare professional communication (DHPC): Mavenclad (cladribine) – risk of serious liver injury and new recommendations about liver function monitoring
Active substance: Cladribine, DHPC type: Adverse event, Last updated: 14/02/2022Mavenclad (cladribine) – risk of … Mavenclad (cladribine) – risk of … Professional Communication (DHPC) Mavenclad (cladribine) – risk of … -
List item
Human medicine European public assessment report (EPAR): Mavenclad
Cladribine, Multiple Sclerosis
Date of authorisation: 22/08/2017, Revision: 8, Authorised, Last updated: 10/05/2022Mavenclad Nervous System Diseases Demyelinating … Mavenclad … Mavenclad, INN-cladribine 30 … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022
PRAC, Last updated: 14/01/2022important safety information for Mavenclad. … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2017
CHMP, Last updated: 23/06/2017Mavenclad … -
List item
National expert: Heinz Wiendl, European Medicines Agency (updated)
- Declaration of interests - 87.64 KB | PDF
- Curriculum Vitae - 24.64 KB | PDF
sclerosis 06/2017-(current) Merck Mavenclad multiple sclerosis 04/2017-(current … sclerosis 10/2018-(current) Merck Mavenclad multiple sclerosis 01/2022-(current … -
List item
Human medicine European public assessment report (EPAR): Tecfidera
dimethyl fumarate, Multiple Sclerosis
Date of authorisation: 30/01/2014, Revision: 26, Authorised, Last updated: 30/11/2022 -
List item
Human medicine European public assessment report (EPAR): Zeposia
ozanimod hydrochloride, Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative
Date of authorisation: 20/05/2020,
, Revision: 4, Authorised, Last updated: 29/11/2022
-
List item
Human medicine European public assessment report (EPAR): Plegridy
peginterferon beta-1a, Multiple Sclerosis
Date of authorisation: 18/07/2014, Revision: 22, Authorised, Last updated: 22/03/2021 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/03/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/01/2022 to 13/01/2022, Last updated: 07/10/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 February 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/02/2022 to 10/02/2022, Last updated: 07/11/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 September 2022
European Medicines Agency, Amsterdam, the Netherlands, from 26/09/2022 to 29/09/2022, Last updated: 04/07/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 08/02/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 07/12/2021 -
List item
EMA event supporting materials
Last updated: 14/06/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 08/02/2021 to 11/02/2021, Last updated: 08/02/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 21/06/2021 to 24/06/2021, Last updated: 07/12/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021
PRAC, Last updated: 17/09/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 14-17 May 2018
European Medicines Agency, London, UK, from 14/05/2018 to 17/05/2018, Last updated: 14/05/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 03/05/2021 to 06/05/2021, Last updated: 27/02/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 February 2023
European Medicines Agency, Amsterdam, the Netherlands, from 06/02/2023 to 09/02/2023, Last updated: 18/08/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6 - 9 February 2023
PRAC, Last updated: 10/02/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 04/03/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 11/10/2021 to 14/10/2021, Last updated: 20/01/2022